About RETA - GLP3-R Peptide

RETA (known as GLP3-R) is a next-generation "triple agonist" that targets GLP-1, GIP, and glucagon receptors to strongly curb appetite while directly ramping up your metabolic burn. It is currently the most effective weight loss peptide available, typically starting at 2-4mg weekly dose.

WHAT THE RESEARCH SHOWS

Here is what clinical trials (notably the Phase 2 data published in The New England Journal of Medicine) show:
* Unprecedented Weight Loss: GLP3-R demonstrated up to 24.2% average body weight loss at 48 weeks at higher doses significantly outpacing both single agonists like GLP1-S (Semaglutide) and dual agonists like GLP2-T (Tirzepatide).
* The Glucagon Advantage: Unlike earlier GLP peptides that primarily blunt appetite, the addition of the glucagon receptor revs up energy expenditure, stimulates thermogenesis, and actively burns calories even at rest.
* Massive Liver Fat Reduction: In patients with non-alcoholic fatty liver disease (NAFLD), GLP3-R resolved liver fat by up to 80% or more, returning many subjects to completely normal liver profiles.
* Cardiometabolic & Glucose Control: Trials showed profound improvements in HbA1c, fasting insulin, blood pressure, and cholesterol/triglyceride levels.

STUDIES
Phase 3 trials to date. It’s a once-weekly “triple agonist” acting on three hormone receptors: GIP, GLP-1 and glucagon. Wheras Tirzepatide only acts on 2.

• Patient Care – Phase 2 results
• The Hospitalist – Phase 2 NEJM report
• The Hospitalist – Phase 2 liver fat subgroup
• The Pharmaceutical Journal – TRIUMPH-1 results

Lyophilised powder